Trial Profile

Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabectedin (Primary) ; Bevacizumab; Hydroxycarbamide
Indications Meningioma
Focus Therapeutic Use

Most Recent Events

06 Jun 2023 Post-hoc results assessing 3D volume growth rate, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
04 May 2022 Results published in the Neuro-Oncology
04 Jun 2019 Primary endpoint (Progression Free Survival (PFS)) has not been met, according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com